Back to Journals » Therapeutics and Clinical Risk Management » Call For Papers

Therapeutics and Clinical Risk Management

ISSN: 1178-203X


The following Article Collections/ Thematic Series are currently open for submissions:

Lymphoproliferation at the crossroad between hematology and immunology: molecular and clinical implications

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Lymphoproliferation at the crossroad between hematology and immunology: molecular and clinical implications" in Therapeutics and Clinical Risk Management.

Lymphoproliferation, clinically expressed with lymphadenopathies, hepato-splenomegaly, or lymphoid organ infiltration, is a common feature of different diseases, ranging from infections to hematologic malignancies. In the recent years, there has also been an increasing interest in the impact of lymphoproliferative features in patients with inborn errors of immunity (IEI), as benign polyclonal lymphoproliferation is one of the leading signs in different IEIs, including the autoimmune lymphoproliferative syndrome and other immune dysregulation disorders. Moreover, the knowledge on lymphoproliferative malignancies israpidly progressing, with the increasing availability of new therapeutic regimens.

Therefore, a deeper understanding of the diseases featured by lymphoproliferation is warranted, in order to improve the recognition and treatment of the main causes of lymphoproliferation, including IEIs and malignancies.

This aim of this Article Collection is to offer an overview of lymphoproliferative diseases, considering the diagnostic aspect (with a specific focus on the new diseases associated with lymphoproliferation) and the therapeutic options in the setting of both polyclonal and malignant lymphoproliferation. Specifically, the possibility to have the contribution from both an immunological and onco-hematological point of view could significantly increase the impact of this Collection. This Article Collection will consider review papers and original research papers.

Keywords

  • Lymphadenopathy
  • Inborn errors of immunity
  • Immune dysregulation
  • Lymphomas
  • Splenomegaly

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 30 November 2024.

Please submit your manuscript on our website, quoting the promo code IHLGQ to indicate that your submission is for consideration in this Article Collection.

Guest Advisors

Giorgio Costagliola, Azienda Ospedaliero Universitaria Pisana (AOUP)

[email protected]

Medical doctor and researcher at the Pediatric Hematology and Oncology Department of the Azienda Ospedaliero Unviersitaria Pisana (AOUP), with a special focus on inborn errors of immunity. Junior member of the European Society for Immunodeficiencies and member of the Associazione Italiana Oncologia ed Ematologia Pediatrica (AIEOP) and Italian Primary Immunodeficiency network (IPINET).

Rita Consolini, University of Pisa

[email protected]

Professor of Pediatrics at the University of Pisa, involved in teaching pediatric and immunology. Medical Doctor 1976 University of Pisa, Italy (pass with distinction). Expertise in Pediatrics (1979), Immunology (1982) and Haematology (1986). Member European Society for Immunodeficiencies (ESID), Associazione Italiana Oncologia ed Ematologia Pediatrica (AIEOP) and Italian Primary Immunodeficiency network (IPINET).

View all papers in this article collection

Unlocking the Secrets of the Nervous System: Unveiling the Biomarkers of Neurological Diseases

Dove Medical Press is pleased to invite you to submit your research to an upcoming Article Collection on "Unlocking the Secrets of the Nervous System: Unveiling the Biomarkers of Neurological Diseases" in Therapeutics and Clinical Risk Management.

This Collection aims to compile groundbreaking research and insights into the biomarkers associated with neurological diseases. Biomarkers play a crucial role in understanding the pathophysiology of neurological disorders, aiding in early diagnosis, prognosis prediction, and monitoring the efficacy of therapeutic interventions. The gathered articles will explore the diverse range of biomarkers, from genetic and protein markers to imaging and clinical biomarkers, that are instrumental in unravelling the complexities of neurological diseases.

The importance of identifying and understanding biomarkers in neurological diseases cannot be overstated. These markers provide valuable information about the disease process, ultimately facilitating personalized medicine approaches and more effective treatments. By elucidating the intricate relationship between biomarkers and neurological diseases, we can unlock new avenues for research and intervention, thereby improving patient outcomes and contributing to the global fight against these debilitating conditions.

We invite authors to submit original research articles, comprehensive reviews, and perspective pieces that delve into the various aspects of biomarkers in neurological diseases. Submissions should focus on topics such as the identification and validation of new biomarkers, the role of biomarkers in disease progression and treatment response, and the challenges and opportunities in translating biomarker research into clinical practice. Through this article collection, we aim to create a valuable resource for researchers, clinicians, and anyone with an interest in the dynamic field of neurological diseases and their associated biomarkers.

Keywords

  • Neurological Diseases
  • Biomarkers
  • Prognosis
  • Disease Monitoring
  • Clinical Applications

All manuscripts submitted to this Article Collection will undergo a full peer-review; the Guest Advisor for this collection will not be handling the manuscripts (unless they are an Editorial Board member). Please review the journal scope and author submission instructions prior to submitting a manuscript.

The deadline for submitting manuscripts is 31 July 2024.

Please submit your manuscript on our website, quoting the promo code RFPYX to indicate that your submission is for consideration in this Article Collection.

Guest Advisor

Xiaoqiao Dong, Affiliated Hangzhou First People's Hospital, Zhejiang University School of Medicine

[email protected]

Dr. Xiaoqiao Dong holds a doctoral degree and is a chief physician and master's degree supervisor. He specializes in clinical work related to traumatic brain injuries, spontaneous cerebral hemorrhage, and subarachnoid hemorrhage, and conducts basic and clinical research on acute brain injuries. Dr. Dong has participated in more than 30 projects, published over 70 SCI articles, received 9 awards for scientific and technological progress, and obtained 3 invention patents.

View all papers in this article collection


Call For Papers

Editor-in-Chief: Professor Garry Walsh


To see where Therapeutics and Clinical Risk Management is indexed online view the Journal Metrics

What is the advantage to you of publishing in Therapeutics and Clinical Risk Management?

  • It is an open access journal which means that your paper is available to anyone in the world to download for free directly from the Dove website.
  • Although Therapeutics and Clinical Risk Management receives a large number of papers, unlike many traditional journals, your paper will not be rejected due to lack of space. We are an electronic journal and there are no limits on the number or size of the papers we can publish.
  • The time from submission to a decision being made on a paper can, in many journals, take some months and this is very frustrating for authors. Therapeutics and Clinical Risk Management has a quicker turnaround time than this. Generally peer review is complete within 3-4 weeks and the editor’s decision within 2-14 days of this. It is therefore very rare to have to wait more than 6 weeks for first editorial decision.
  • Many authors have found that our peer reviewer’s comments substantially add to their final papers.

To recover our editorial and production costs and continue to provide our content at no cost to readers we charge authors or their institution an article publishing charge.

PubMed Central
Therapeutics and Clinical Risk Management is indexed on PubMed Central (title abbreviation: Ther Clin Risk Manag).  All published papers in this journal are submitted to PubMed for indexing straight away.

Become a Favored Author and receive real benefits
If you haven't already joined the Dove Press Favored Author Program I would encourage you to do so. Why? To receive real benefits like fast-tracking and a personal co-ordinator for your paper, as well as a discount on the publication processing fee.
Click here to go through to the Favored Author signup page.

Yours sincerely
Professor Garry Walsh
Editor-in-Chief
Therapeutics and Clinical Risk Management

Email: Editor-in-Chief